Compare Axogen Inc (AXGN) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs C.H. Robinson Worldwide, Inc. — how do they compare? Axogen Inc trades at $49 (market cap $2.61B), while C.H. Robinson Worldwide, Inc. trades at $147.83 (market cap $16.96B). The key difference: C.H. Robinson Worldwide, Inc. is far larger — about 6.5× Axogen Inc's market cap, and C.H. Robinson Worldwide, Inc. pays a 1.74% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | CHRW | |
|---|---|---|
Market Cap | $2.61B | $16.96B |
Sector | Technology | Industrials |
52-Week High | $48.48 | $209.42 |
52-Week Low | $14.16 | $118.77 |
Enterprise Value | $2.52B | $18.78B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.
The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.
CHRW trades at $147.68, down 0.41% with bearish technical signals, though recent earnings beats and strong profitability metrics provide fundamental support. The company reported Q2 2026 EPS of $1.61, beating expectations, with revenue of $16.23B in 2025 and net income margin improving to 3.73%. Analyst consensus remains positive with a $193 price target, while recent news highlights dividend declarations and institutional buying activity.
Outlook remains cautiously optimistic given earnings momentum and solid ROE of 37.12%, though technical weakness and legal challenges pose near-term risks. The stock offers growth potential with reasonable valuation (P/E 27.7) but faces headwinds from freight demand volatility and competitive pressures in logistics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
